NSB — Neuroscientific Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- AU$7.66m
- AU$4.33m
- AU$5.06m
- 75
- 65
- 23
- 56
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.119 | 0.076 | 1.05 | 0.068 | 5.06 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.78 | 2.94 | 4.22 | 10.5 | 6.12 |
Operating Profit | -1.66 | -2.87 | -3.18 | -10.4 | -1.06 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.66 | -2.87 | -3.18 | -10.4 | -1.07 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.66 | -2.87 | -3.18 | -10.4 | -1.07 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.66 | -2.87 | -3.18 | -10.4 | -1.07 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.66 | -2.87 | -3.18 | -10.4 | -1.07 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.021 | -0.037 | -0.022 | -0.073 | -0.007 |